Literature DB >> 19411248

Low pH-dependent hepatitis C virus membrane fusion depends on E2 integrity, target lipid composition, and density of virus particles.

Sibylle Haid1, Thomas Pietschmann, Eve-Isabelle Pécheur.   

Abstract

Hepatitis C virus (HCV) is an enveloped, positive strand RNA virus of about 9.6 kb. Like all enveloped viruses, the HCV membrane fuses with the host cell membrane during the entry process and thereby releases the genome into the cytoplasm, initiating the viral replication cycle. To investigate the features of HCV membrane fusion, we developed an in vitro fusion assay using cell culture-produced HCV and fluorescently labeled liposomes. With this model we could show that HCV-mediated fusion can be triggered in a receptor-independent but pH-dependent manner and that fusion of the HCV particles with liposomes is dependent on the viral dose and on the lipid composition of the target membranes. In addition CBH-5, an HCV E2-specific antibody, inhibited fusion in a dose-dependent manner. Interestingly, point mutations in E2, known to abrogate HCV glycoprotein-mediated fusion in a cell-based assay, altered or even abolished fusion in the liposome-based assay. When assaying the fusion properties of HCV particles with different buoyant density, we noted higher fusogenicity of particles with lower density. This could be attributable to inherently different properties of low density particles, to association of these particles with factors stimulating fusion, or to co-flotation of factors enhancing fusion activity in trans. Taken together, these data show the important role of lipids of both the viral and target membranes in HCV-mediated fusion, point to a crucial role played by the E2 glycoprotein in the process of HCV fusion, and reveal an important behavior of HCV of different densities with regard to fusion.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19411248      PMCID: PMC2719405          DOI: 10.1074/jbc.M109.014647

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  82 in total

1.  Low-pH-dependent fusion of Sindbis virus with receptor-free cholesterol- and sphingolipid-containing liposomes.

Authors:  J M Smit; R Bittman; J Wilschut
Journal:  J Virol       Date:  1999-10       Impact factor: 5.103

2.  [On so-called oxide-wax, a solid polyethyleneglycol].

Authors:  G KARBER
Journal:  Naunyn Schmiedebergs Arch Exp Pathol Pharmakol       Date:  1951

Review 3.  Hepatitis C virus particles and lipoprotein metabolism.

Authors:  Patrice André; Gabriel Perlemuter; Agata Budkowska; Christian Bréchot; Vincent Lotteau
Journal:  Semin Liver Dis       Date:  2005-02       Impact factor: 6.115

4.  Characterization of hepatitis C virus E2 glycoprotein interaction with a putative cellular receptor, CD81.

Authors:  M Flint; C Maidens; L D Loomis-Price; C Shotton; J Dubuisson; P Monk; A Higginbottom; S Levy; J A McKeating
Journal:  J Virol       Date:  1999-08       Impact factor: 5.103

5.  Prevention of hepatitis C virus infection in chimpanzees by hyperimmune serum against the hypervariable region 1 of the envelope 2 protein.

Authors:  P Farci; A Shimoda; D Wong; T Cabezon; D De Gioannis; A Strazzera; Y Shimizu; M Shapiro; H J Alter; R H Purcell
Journal:  Proc Natl Acad Sci U S A       Date:  1996-12-24       Impact factor: 11.205

6.  The low-density lipoprotein receptor plays a role in the infection of primary human hepatocytes by hepatitis C virus.

Authors:  Sonia Molina; Valérie Castet; Chantal Fournier-Wirth; Lydiane Pichard-Garcia; Rachel Avner; Dror Harats; Joseph Roitelman; Ronald Barbaras; Pierre Graber; Paola Ghersa; Moshe Smolarsky; Ada Funaro; Fabio Malavasi; Dominique Larrey; Joliette Coste; Jean-Michel Fabre; Antonio Sa-Cunha; Patrick Maurel
Journal:  J Hepatol       Date:  2006-11-13       Impact factor: 25.083

7.  Binding of hepatitis C virus to CD81.

Authors:  P Pileri; Y Uematsu; S Campagnoli; G Galli; F Falugi; R Petracca; A J Weiner; M Houghton; D Rosa; G Grandi; S Abrignani
Journal:  Science       Date:  1998-10-30       Impact factor: 47.728

8.  Initiation of hepatitis C virus infection is dependent on cholesterol and cooperativity between CD81 and scavenger receptor B type I.

Authors:  Sharookh B Kapadia; Heidi Barth; Thomas Baumert; Jane A McKeating; Francis V Chisari
Journal:  J Virol       Date:  2006-10-18       Impact factor: 5.103

9.  euHCVdb: the European hepatitis C virus database.

Authors:  Christophe Combet; Nicolas Garnier; Céline Charavay; Delphine Grando; Daniel Crisan; Julien Lopez; Alexandre Dehne-Garcia; Christophe Geourjon; Emmanuel Bettler; Chantal Hulo; Philippe Le Mercier; Ralf Bartenschlager; Helmut Diepolder; Darius Moradpour; Jean-Michel Pawlotsky; Charles M Rice; Christian Trépo; François Penin; Gilbert Deléage
Journal:  Nucleic Acids Res       Date:  2006-11-16       Impact factor: 16.971

10.  Immunogenic and functional organization of hepatitis C virus (HCV) glycoprotein E2 on infectious HCV virions.

Authors:  Zhen-Yong Keck; Jinming Xia; Zhaohui Cai; Ta-Kai Li; Ania M Owsianka; Arvind H Patel; Guangxiang Luo; Steven K H Foung
Journal:  J Virol       Date:  2006-11-01       Impact factor: 5.103

View more
  39 in total

1.  Impact of intra- and interspecies variation of occludin on its function as coreceptor for authentic hepatitis C virus particles.

Authors:  Sandra Ciesek; Sandra Westhaus; Melanie Wicht; Ilka Wappler; Sylvana Henschen; Christoph Sarrazin; Nabila Hamdi; Ahmed I Abdelaziz; Christian P Strassburg; Heiner Wedemeyer; Michael P Manns; Thomas Pietschmann; Thomas von Hahn
Journal:  J Virol       Date:  2011-06-01       Impact factor: 5.103

2.  Apolipoprotein E codetermines tissue tropism of hepatitis C virus and is crucial for viral cell-to-cell transmission by contributing to a postenvelopment step of assembly.

Authors:  Kathrin Hueging; Mandy Doepke; Gabrielle Vieyres; Dorothea Bankwitz; Anne Frentzen; Juliane Doerrbecker; Frauke Gumz; Sibylle Haid; Benno Wölk; Lars Kaderali; Thomas Pietschmann
Journal:  J Virol       Date:  2013-10-30       Impact factor: 5.103

3.  Mouse-specific residues of claudin-1 limit hepatitis C virus genotype 2a infection in a human hepatocyte cell line.

Authors:  Sibylle Haid; Marc P Windisch; Ralf Bartenschlager; Thomas Pietschmann
Journal:  J Virol       Date:  2009-11-04       Impact factor: 5.103

Review 4.  The divergence, actions, roles, and relatives of sodium-coupled bicarbonate transporters.

Authors:  Mark D Parker; Walter F Boron
Journal:  Physiol Rev       Date:  2013-04       Impact factor: 37.312

5.  Hepatitis C virus hypervariable region 1 modulates receptor interactions, conceals the CD81 binding site, and protects conserved neutralizing epitopes.

Authors:  Dorothea Bankwitz; Eike Steinmann; Julia Bitzegeio; Sandra Ciesek; Martina Friesland; Eva Herrmann; Mirjam B Zeisel; Thomas F Baumert; Zhen-yong Keck; Steven K H Foung; Eve-Isabelle Pécheur; Thomas Pietschmann
Journal:  J Virol       Date:  2010-03-31       Impact factor: 5.103

6.  Systems virology identifies a mitochondrial fatty acid oxidation enzyme, dodecenoyl coenzyme A delta isomerase, required for hepatitis C virus replication and likely pathogenesis.

Authors:  Angela L Rasmussen; Deborah L Diamond; Jason E McDermott; Xiaoli Gao; Thomas O Metz; Melissa M Matzke; Victoria S Carter; Sarah E Belisle; Marcus J Korth; Katrina M Waters; Richard D Smith; Michael G Katze
Journal:  J Virol       Date:  2011-09-14       Impact factor: 5.103

7.  Functional Analysis of Hepatitis C Virus (HCV) Envelope Protein E1 Using a trans-Complementation System Reveals a Dual Role of a Putative Fusion Peptide of E1 in both HCV Entry and Morphogenesis.

Authors:  Yimin Tong; Xiaojing Chi; Wei Yang; Jin Zhong
Journal:  J Virol       Date:  2017-03-13       Impact factor: 5.103

8.  Phenothiazines inhibit hepatitis C virus entry, likely by increasing the fluidity of cholesterol-rich membranes.

Authors:  Ana M Chamoun-Emanuelli; Eve-Isabelle Pecheur; Rudo L Simeon; Da Huang; Paul S Cremer; Zhilei Chen
Journal:  Antimicrob Agents Chemother       Date:  2013-03-25       Impact factor: 5.191

9.  Characterization of hepatitis C virus recombinants with chimeric E1/E2 envelope proteins and identification of single amino acids in the E2 stem region important for entry.

Authors:  Thomas H R Carlsen; Troels K H Scheel; Santseharay Ramirez; Steven K H Foung; Jens Bukh
Journal:  J Virol       Date:  2012-11-14       Impact factor: 5.103

10.  The Synthetic Antiviral Drug Arbidol Inhibits Globally Prevalent Pathogenic Viruses.

Authors:  Eve-Isabelle Pécheur; Viktoriya Borisevich; Peter Halfmann; John D Morrey; Donald F Smee; Mark Prichard; Chad E Mire; Yoshihiro Kawaoka; Thomas W Geisbert; Stephen J Polyak
Journal:  J Virol       Date:  2016-01-06       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.